|Table of Contents|

Clinical analysis of 18 cases of tumor lysis syndrome in childhood acute lymphoblastic leukemia

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 04
Page:
737-740
Research Field:
Publishing date:

Info

Title:
Clinical analysis of 18 cases of tumor lysis syndrome in childhood acute lymphoblastic leukemia
Author(s):
DUN Jianxin; CUI Dongyan; ZHANG Ai; LIU Aiguo; HU Qun
Department of Pediatric Hematology,Tongji Hospital,Tongji Medical College of Huazhong University of Science and Technology,Hubei Wuhan 430030,China.
Keywords:
children; acute lymphoblastic leukemia; tumor lysis syndrome
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2023.04.027
Abstract:
Objective:To evaluate the clinical features of tumor lysis syndrome(TLS)in childhood acute lymphoblastic leukemia(ALL),and to analyse the risk factors and prognosis of TLS.Methods:Totally 253 children with ALL were included retrospectively who were newly diagnosed in our hospital from January 1st 2015 to June 30th 2020.The risk factors of TLS and the effects of TLS on the prognosis of children with ALL were analyzed.Results:In the 253 children,18 chidfren （7.1%） developed TLS.The ratio of male-female was 2.6∶1 the median age was 8.1 years old.Compared with children without TLS,children with TLS were tend to present with sinus tachycardia,abnormal forearm myocardial repolarization and prolonged QT interval(P<0.05).There was no significant difference between TLS children presenting Hyperleukocytosis(WBC≥50×109/L)and those not presenting hyperleukocytosis in blood uric acid,creatinine,LDH,potassium,calcium correction and Ccr(P>0.05).LDH≥900 U/L was an independent risk factor for TLS.There were no significant differences in EFS and OS in patients with TLS compared to patients without TLS(P>0.05).Conclusion:Children with LDH≥900 U/L has higher incidence of TLS.TLS is not a prognostic factor of EFS and OS in children with ALL.

References:

［1］ BARBAR T,JAFFER SATHICK I.Tumor lysis syndrome［J］.Adv Chronic Kidney Dis,2021,28(5):438-446.
［2］ RAHMANI B,PATEL S,SEYAM O,et al.Current understanding of tumor lysis syndrome［J］.Hematological Oncology,2019,37(5):537-547.
［3］ SALEH K,MICHOT JM,CAMARA-CLAYETTE V,et al.Burkitt and Burkitt-like Lymphomas:A systematic review［J］.Current Oncology Reports,2020,22(4):33.
［4］ DURANI U,HOGAN WJ.Emergencies in haematology:Tumour lysis syndrome［J］.British Journal of Haematology,2020,188(4):494-500.
［5］ LUPUSORU G,AILINCAI I,FRATILA G,et al.Tumor lysis syndrome:An endless challenge in onco-nephrology［J］.Biomedicines,2022,10(5):1012.
［6］ XUE Y,CHEN J,GAO S,et al.Clinical characteristics of tumor lysis syndrome in childhood acute lymphoblastic leukemia［J］.Scientific Reports,2021,11(1):9656.
［7］ CORTES J,MOORE JO,MAZIARZ RT,et al.Control of plasma uric acid in adults at risk for tumor lysis syndrome:Efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study［J］.Journal of Clinical Oncology,2010,28(27):4207-4213.
［8］ 蒋理,郑胡镛.儿童肿瘤溶解综合征高尿酸血症的诊治进展［J］.首都医科大学学报,2019,40(03):483-487. JIANG L,ZHENG HY.Progress in diagnosis and treatment of hyperuricemia in children with tumor lysis syndrome［J］.Joumal of Capital Medical University,2019,40(03):483-487.
［9］ CHEUK DK,CHIANG AK,CHAN GC,et al.Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer［J］.Cochrane Database of Systematic Reviews,2017,2017(3):CD006945.
［10］ CAIRO MS,COIFFIER B,REITER A,et al.Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome(TLS)in adults and children with malignant diseases:An expert TLS panel consensus［J］.British Journal of Haematology,2010,149(4):578-586.
［11］ SPINA M,NAGY Z,RIBERA JM,et al.FLORENCE:A randomized,double-blind,phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome(TLS)in patients with hematologic malignancies at intermediate to high TLS risk［J］.Ann Oncol,2015,26(10):2155-2161.
［12］ WILSON FP,BERNS JS.Tumor lysis syndrome:New challenges and recent advances［J］.Adv Chronic Kidney Dis,2014,21(1):18-26.
［13］ MATUSZKIEWICZ-ROWINSKA J,MALYSZKO J.Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress［J］.Kidney and Blood Pressure Research,2020,45(5):645-660.
［14］ ABU-ALFA AK,YOUNES A.Tumor lysis syndrome and acute kidney injury:Evaluation,prevention,and management［J］.Am J Kidney Dis,2010,55(5 Suppl 3):S1-13.
［15］ 黄礼彬.儿童肿瘤溶解综合征诊疗指南［J］.中国实用儿科杂志,2021,36(12):890-896. HUANG LB.Guidelines for the diagnosis and treatment of tumor lysis syndrome in children［J］.Chinese Journal of Practical Pediatrics,2021,36(12):890-896.

Memo

Memo:
-
Last Update: 1900-01-01